Novartis Ag (NVS) Gross Profit Growth (3y) (2012 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Gross Profit Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
44.89% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
3.95% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
9.39% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
4.61% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
10.24% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
3.66% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
1.34% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-2.75% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
598.52% |
| Dec 31, 2024 |
1,001.75% |
| Jun 30, 2024 |
786.07% |
| Dec 31, 2023 |
-1.42% |
| Jun 30, 2023 |
3.54% |
| Mar 31, 2023 |
2,945.55% |
| Mar 31, 2022 |
17.42% |
| Dec 31, 2021 |
-74.84% |
| Sep 30, 2021 |
-66.31% |
| Jun 30, 2021 |
-26.02% |
| Mar 31, 2021 |
-4.35% |
| Dec 31, 2020 |
175.67% |
| Sep 30, 2020 |
-72.12% |
| Jun 30, 2020 |
27.33% |
| Mar 31, 2020 |
-37.47% |
| Mar 31, 2019 |
3,057.65% |
| Dec 31, 2018 |
-3.33% |
| Sep 30, 2018 |
913,057.51% |
| Mar 31, 2018 |
2,670.98% |
| Dec 31, 2017 |
20,559.05% |
| Sep 30, 2017 |
19,289.45% |
| Mar 31, 2017 |
10,458.96% |
| Sep 30, 2015 |
-99.06% |
| Mar 31, 2015 |
-7.75% |
| Dec 31, 2014 |
-46.95% |
| Sep 30, 2014 |
-47.03% |
| Mar 31, 2014 |
-6.89% |
| Sep 30, 2012 |
-52.62% |
| Jun 30, 2012 |
-50.54% |
| Mar 31, 2012 |
-49.28% |
